Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Net Margin (2016 - 2025)

Historic Net Margin for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 77.66%.

  • Coherus Oncology's Net Margin fell 5312000.0% to 77.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 194.53%, marking a year-over-year increase of 402000.0%. This contributed to the annual value of 10.68% for FY2024, which is 1031600.0% up from last year.
  • Per Coherus Oncology's latest filing, its Net Margin stood at 77.66% for Q3 2025, which was down 5312000.0% from 3341.42% recorded in Q2 2025.
  • Coherus Oncology's Net Margin's 5-year high stood at 7405.16% during Q1 2024, with a 5-year trough of 233.47% in Q1 2023.
  • Its 5-year average for Net Margin is 549.34%, with a median of 62.34% in 2021.
  • Its Net Margin has fluctuated over the past 5 years, first surged by 76386300bps in 2024, then crashed by -75258400bps in 2025.
  • Coherus Oncology's Net Margin (Quarter) stood at 62.34% in 2021, then plummeted by -108bps to 129.81% in 2022, then surged by 33bps to 87.03% in 2023, then surged by 192bps to 79.66% in 2024, then dropped by -3bps to 77.66% in 2025.
  • Its last three reported values are 77.66% in Q3 2025, 3341.42% for Q2 2025, and 120.69% during Q1 2025.